Gyre Therapeutics, Inc. (GYRE) Tops Q3 Earnings and Revenue EstimatesZacks Investment Research • 11/06/26
Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesGlobeNewsWire • 11/05/26
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/07/26
Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewsWire • 08/07/26
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the FirmNewsfile Corp • 05/28/26
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis TreatmentGlobeNewsWire • 05/12/26
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/26
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateGlobeNewsWire • 05/07/26
Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyGlobeNewsWire • 05/04/26
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentGlobeNewsWire • 03/17/26
Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewsWire • 03/12/26
Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and PipelineGlobeNewsWire • 03/02/26
Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA MeetingGlobeNewsWire • 01/05/26
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business UpdateGlobeNewsWire • 11/07/25
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of PneumoconiosisGlobeNewsWire • 10/15/25
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025GlobeNewsWire • 10/14/25
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceGlobeNewsWire • 09/05/25
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of DirectorsGlobeNewsWire • 08/22/25